

*James D. Cullman*  
cfu/ml, wherein said retrovirus preparation has a titer of HT1080 cells of greater than  $10^7$  cfu/ml.

REMARKS

By this amendment claims 1-3, 6-11, 57, 58, and 61-68 have been cancelled without prejudice, and claims 4 and 5 have been rewritten in independent form. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

With this Amendment claims 4, 5 and 37 through 56 remain in this application.

It is believed that the foregoing amendment places this case in condition for allowance and notice to that effect is earnestly solicited. No additional fees are seen as being necessary in connection with this amendment. However, the Examiner is authorized to charge any additional fees or credit any overpayment to Deposit Account 16-2230. If any issues remain, the Examiner is urged to contact the undersigned by telephone for a prompt resolution thereof.

Respectfully submitted



Louis C. Cullman  
Registration No. 39,645

Dated: March 29, 2001

CHIRON CORPORATION  
Intellectual Property - R 440  
P. O. Box 8097  
Emeryville, California 94662-8097  
Telephone: (510) 923-2719 \* Facsimile: (510) 655-3542



**VERSION WITH MARKINGS TO SHOW CHANGES**

Claims 1-3, 6-11, 57, 58, and 61-68 have been cancelled

Claims 4 and 5 have been amended as follows:

4. (Amended) A preparation of replication defective recombinant retrovirus expressing human factor VIII protein, wherein said recombinant retrovirus is capable of infecting human cells and is resistant to degradation by human complement, [The recombinant retrovirus preparation of claim 1,] wherein said recombinant retrovirus preparation has a titer of HT1080 cells of greater than  $10^6$  cfu/ml.

5. (Amended) A preparation of replication defective recombinant retrovirus expressing human factor VIII protein, wherein said recombinant retrovirus is capable of infecting human cells and is resistant to degradation by human complement wherein said recombinant retrovirus preparation has a titer of HT1080 cells of greater than  $10^6$  cfu/ml, [The recombinant retrovirus preparation of claim 4,] wherein said retrovirus preparation has a titer of HT1080 cells of greater than  $10^7$  cfu/ml.